1 |
Fremin C, Meloche S (2010). From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol, 3, 8.
DOI
|
2 |
Flaherty KT, Lee SJ, Zhao F, et al (2013). Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol, 31, 373-9.
DOI
ScienceOn
|
3 |
Flaherty KT, Schiller J, Schuchter LM, et al (2008). A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res, 14, 4836-42.
DOI
ScienceOn
|
4 |
Copas J, Shi JQ (2000). Meta-analysis, funnel plots and sensitivity analysis. Biostatistics, 1, 247-62.
DOI
|
5 |
Berlin JA (1995). Invited commentary: benefits of heterogeneity in metaanalysis of data from epidemiologic studies. Am J Epidemiol, 142, 383-7.
|
6 |
Bodoky G, Timcheva C, Spigel DR, et al (2012). A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs, 30, 1216-23.
DOI
|
7 |
Chang L, Karin M (2001). Mammalian MAP kinase signalling cascades. Nature, 410, 37-40.
DOI
ScienceOn
|
8 |
Curtin JA, Fridlyand J, Kageshita T, et al (2005). Distinct sets of genetic alterations in melanoma. N Engl J Med, 353, 2135-47.
DOI
ScienceOn
|
9 |
Davies H, Bignell GR, Cox C, et al (2002). Mutations of the BRAF gene in human cancer. Nature, 417, 949-54.
DOI
ScienceOn
|
10 |
DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
DOI
ScienceOn
|
11 |
Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D (2013). MEK and the inhibitors: from bench to bedside. J Hematol Oncol, 6, 27.
DOI
|
12 |
Almoguera C, Shibata D, Forrester K, et al (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 53, 549-54.
DOI
ScienceOn
|
13 |
Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR (1995). A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA, 92, 7686-9.
DOI
ScienceOn
|
14 |
English J, Pearson G, Wilsbacher J, et al (1999). New insights into the control of MAP kinase pathways. Exp Cell Res, 253, 255-70.
DOI
ScienceOn
|
15 |
Peyssonnaux C, Eychene A (2001). The Raf/MEK/ERK pathway: New concepts of activation. Biol Cell, 93, 53-62.
DOI
ScienceOn
|
16 |
Moher D, Pham B, Jones A, et al (1998). Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet, 352, 609-13.
DOI
ScienceOn
|
17 |
O'Neil BH, Goff LW, Kauh JS, et al (2011). Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 29, 2350-6.
DOI
|
18 |
Pearson G, Robinson F, Beers Gibson T, et al (2001). Mitogenactivated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev, 22, 153-183.
|
19 |
Pimienta G, Pascual J (2007). Canonical and alternative MAPK signaling. Cell Cycle, 6, 2628-32.
DOI
ScienceOn
|
20 |
Raman M, Chen W, Cobb MH (2007). Differential regulation and properties of MAPKs. Oncogene, 26, 3100-12.
DOI
ScienceOn
|
21 |
Robert C, Dummer R, Gutzmer R, et al (2013). Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol, 14, 733-40.
DOI
|
22 |
Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J (2006). Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods, 11, 193-206.
DOI
ScienceOn
|
23 |
Robins J, Greenland S, Breslow NE (1986). A general estimator for the variance of the Mantel-Haenszel odds ratio. Am J Epidemiol, 124, 719-23.
|
24 |
Bekaii-Saab T, Phelps MA, Li X, et al (2011). Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol, 29, 2357-63.
DOI
|
25 |
Bennouna J, Lang I, Valladares-Ayerbes M, et al (2011). A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs, 29, 1021-8.
DOI
|
26 |
Hainsworth JD, Cebotaru CL, Kanarev V, et al (2010). A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol, 5, 1630-6.
DOI
|
27 |
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
DOI
ScienceOn
|
28 |
Ho AL, Grewal RK, Leboeuf R, et al (2013). Selumetinibenhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med, 368, 623-32.
DOI
|
29 |
Kirkwood JM, Bastholt L, Robert C, et al (2012). Phase II, openlabel, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res, 18, 555-67.
DOI
|
30 |
Krishna M, Narang H (2008). The complexity of mitogenactivated protein kinases (MAPKs) made simple. Cell Mol Life Sci, 65, 3525-44.
DOI
ScienceOn
|
31 |
Messersmith WA, Hidalgo M, Carducci M, Eckhardt SG (2006). Novel targets in solid tumors: MEK inhibitors. Clin Adv Hematol Oncol, 4, 831-6.
|
32 |
Moher D, Liberati A, Tetzlaff J, Altman DG (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol, 62, 1006-12.
DOI
|
33 |
Wortzel I, Seger R (2011). The ERK cascade: distinct functions within various subcellular organelles. Genes Cancer, 2, 195-209.
DOI
|
34 |
Shaul YD, Seger R (2007). The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta, 1773, 1213-26.
DOI
|
35 |
Smit VT, Boot AJ, Smits AM, et al (1988). KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res, 16, 7773-82.
DOI
ScienceOn
|
36 |
Wang D, Boerner SA, Winkler JD, Lorusso PM (2007). Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta, 1773, 1248-55.
DOI
|
37 |
Wright CJ, McCormack PL (2013). Trametinib: first global approval. Drugs, 73, 1245-54.
DOI
|
38 |
Yeh TC, Marsh V, Bernat BA, et al (2007). Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogenactivated protein kinase kinase 1/2 inhibitor. Clin Cancer Res, 13, 1576-83.
DOI
|
39 |
Robinson MJ, Cobb MH (1997). Mitogen-activated protein kinase pathways. Curr Opin Cell Biol, 9, 180-6.
DOI
ScienceOn
|
40 |
Schaeffer HJ, Weber MJ (1999). Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol, 19, 2435-44.
|
41 |
Janne PA, Shaw AT, Pereira JR, et al (2013). Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol, 14, 38-47.
DOI
|
42 |
Farley J, Brady WE, Vathipadiekal V, et al (2013). Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol, 14, 134-40.
DOI
|